Amarin Corporation plc Logo
VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020
August 29, 2020 03:13 ET | Amarin Corporation plc
Primary endpoint of slowed coronary plaque progression reported to have been met with VASCEPA Significant coronary plaque regression of low attenuation plaque (LAP) reported with VASCEPA provides...
Amarin Corporation plc Logo
Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology
August 17, 2020 07:00 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new data that add to the growing body of knowledge on VASCEPA®...
Amarin Corporation plc Logo
Les données cliniques les plus récentes sur VASCEPA® (Icosapent éthyl) administré à des patients présentant un risque cardiovasculaire résiduel seront présentées au Congrès de l'ESC 2020, la réunion annuelle de la Société européenne de cardiologie
August 17, 2020 07:00 ET | Amarin Corporation plc
DUBLIN, Irlande et BRIDGEWATER, N.J., 17 août 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) a annoncé aujourd'hui que de nouvelles données confortent les preuves de plus en plus...
Amarin Corporation plc Logo
Präsentation der aktuellen klinischen Forschung zur Beurteilung von VASCEPA® (Icosapent-Ethyl) bei Patienten mit kardiovaskulärem Restrisiko beim ESC-Kongress 2020 (Jahrestagung der Europäischen Gesellschaft für Kardiologie)
August 17, 2020 07:00 ET | Amarin Corporation plc
DUBLIN (Irland) und BRIDGEWATER (New Jersey, USA), Aug. 17, 2020 (GLOBE NEWSWIRE) -- Die Amarin Corporation plc (NASDAQ:AMRN) hat heute die Vorstellung neuer Daten als Beitrag zum wachsenden...
Amarin Corporation plc Logo
El estudio clínico de más reciente realización que evalúa VASCEPA® (etilo de icosapento) en pacientes con riesgo cardiovascular residual se va a presentar en el Congreso de la ESC del 2020, la cita anual de la Sociedad Europea de Cardiología
August 17, 2020 07:00 ET | Amarin Corporation plc
DUBLÍN (Irlanda) y BRIDGEWATER (Nueva Jersey, EE. UU.), Aug. 17, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ha anunciado hoy que se presentarán datos nuevos que...
Amarin Corporation plc Logo
Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent ethyl) in Reducing Viral Upper Respiratory Infections, Including COVID-19 and Flu, and the Clinical Severity of Such Infections
August 07, 2020 12:12 ET | Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for an investigator-initiated trial to study the effects of...
Amarin Corporation plc Logo
Amarin annonce ses projets pour maximiser le potentiel révolutionnaire de VASCEPA® (icosapent éthyl) en Europe
August 06, 2020 09:38 ET | Amarin Corporation plc
Amarin va créer une organisation dédiée pour conserver une valeur substantielle de l'un des médicaments cardiovasculaires les plus attendus depuis des décennies Un dirigeant commercial chevronné...
Amarin Corporation plc Logo
Amarin kündigt Pläne zur Maximierung des Blockbuster-Potenzials von VASCEPA® (Icosapent-Ethyl) in Europa an
August 06, 2020 09:38 ET | Amarin Corporation plc
Amarin baut engagierte Organisation auf, um den erheblichen Wert eines der am meisten erwarteten kardiovaskulären Arzneimittel seit Jahrzehnten zu erhalten Erfahrene Führungskraft im Bereich der...
Amarin Corporation plc Logo
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe
August 04, 2020 10:38 ET | Amarin Corporation plc
Amarin to Build Dedicated Organization to Retain Substantial Value of One of the Most Anticipated Cardiovascular Drug Products in Decades Veteran Cardiovascular Commercial Executive Hired to Lead...
Amarin Corporation plc Logo
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe
August 04, 2020 06:30 ET | Amarin Corporation plc
Amarin to Build Dedicated Organization to Retain Substantial Value of One of the Most Anticipated Cardiovascular Drug Products in Decades Veteran Cardiovascular Commercial Executive Hired to Lead...